拜唐苹，适合心血管疾病患者和口服降糖药.ppt

拜唐苹上市监测研究对27803例糖尿病患者（其中2型糖尿病患者26004例）进行观察，经过拜唐苹单药和联合治疗超过12周，总体人群低血糖的发生风险为0.07%，其中年龄小于70岁的患者中低血糖的发生风险为0.06%，年龄在70岁以上的患者中低血糖的发生风险仅为0.09%。 OBJECTIVE: The efficacy and tolerability of acarbose were examined in a postmarketing surveillance study of 27 803 patients with diabetes mellitus (26 044 were diagnosed as having type 2 diabetes) over a 12-week treatment period. PATIENTS AND M ethods: Overall efficacy data were reported for type 1 and type 2 diabetes, and a detailed data analysis was conducted for patients with type 2 diabetes. Tolerability was described for the total group. Of the type 2 di